Nilotinib in the Early Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)


Nilotinib in the Early Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Slides from presentations at ASH 2010 and transcribed comments from a recent interview with Susan M O’Brien, MD (1/4/11)

Hughes TP et al. ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Proc ASH 2010;Abstract 207.

Yeung DT et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: Interim results from the TIDEL-II trial. Proc ASH 2010;Abstract 209.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.